VEXAS Syndrome
Symptoms, Doctors, Treatments, Advances & More

VEXAS Syndrome Overview

Save information for later
Sign Up

Learn About VEXAS Syndrome

What is the definition of VEXAS Syndrome?
VEXAS syndrome is a severe inflammatory syndrome caused by a genetic mutation in bone marrow.
What are the symptoms of VEXAS Syndrome?
Symptoms of VEXAS syndrome usually occur between 45 and 80 years of age and may include recurrent fevers, inflammation of the blood vessels, fluid and infections in the lungs, skin and eye inflammation, deep vein clots, joint pain, infections of the cartilage of the ear and nose, anemia, and sensorineural hearing loss.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for VEXAS Syndrome?
There is currently no standard treatment for VEXAS syndrome. However, glucocorticoids have provided some symptom relief. Researchers are currently investigating bone marrow transplants and gene editing as possible treatments for VEXAS syndrome.
Who are the top VEXAS Syndrome Local Doctors?
Elite in VEXAS Syndrome
Mael Heiblig
Elite in VEXAS Syndrome
Mael Heiblig
Lyon, FR 

Mael Heiblig practices practicing medicine in Lyon, France. Mr. Heiblig is rated as an Elite expert by MediFind in the treatment of VEXAS Syndrome. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses VEXAS Syndrome, Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), and Bone Marrow Transplant.

Elite in VEXAS Syndrome
Arsene M. Mekinian
Elite in VEXAS Syndrome
Arsene M. Mekinian
Paris, FR 

Arsene Mekinian practices practicing medicine in Paris, France. Mr. Mekinian is rated as an Elite expert by MediFind in the treatment of VEXAS Syndrome. He is also highly rated in 47 other conditions, according to our data. His clinical expertise encompasses VEXAS Syndrome, Takayasu Arteritis, Vasculitis, Bone Marrow Transplant, and Intrauterine Device Insertion.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in VEXAS Syndrome
Dr. David B. Beck
Medical Genetics | Rheumatology
Elite in VEXAS Syndrome
Dr. David B. Beck
Medical Genetics | Rheumatology

New York University

333 E 38th St, 
New York, NY 
646-356-9400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Beck is a Medical Genetics specialist and a Rheumatologist practicing medicine in New York, New York. Dr. Beck is rated as an Elite provider by MediFind in the treatment of VEXAS Syndrome. He is also highly rated in 2 other conditions, according to our data. His clinical expertise encompasses VEXAS Syndrome, Relapsing Polychondritis, Hypotonia, and Polyarteritis Nodosa.

View All Doctors
What are the latest VEXAS Syndrome Clinical Trials?
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Who is this study for: Patients with VEXAS syndrome
Enrollment Status: Recruiting
Publish Date: April 02, 2026
Intervention Type: Procedure, Drug, Radiation
Study Drugs: Post-Transplant Cyclophosphamide, Cyclophosphamide, Fludarabine, Busulfan, Sirolimus, Mycophenolate mofetil, Busulfan
Study Phase: Phase 2

Background: Allogeneic hematopoietic stem cell transplant involves taking blood stem cells from a donor and giving them to a recipient. The transplants are used to treat certain diseases and cancers. Researchers want to see if the transplant can treat VEXAS Syndrome.

Match to trials
Find the right clinical trials for you in under a minute
Get started
PAXIS: A Randomized, Double-blind, Placebo-controlled Dose-finding Phase 2 Study (Part 1) Followed by an Open-label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients With VEXAS Syndrome
PAXIS: A Randomized, Double-blind, Placebo-controlled Dose-finding Phase 2 Study (Part 1) Followed by an Open-label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients With VEXAS Syndrome
Enrollment Status: Recruiting
Publish Date: March 12, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 participants will be enrolled, randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. Randomization will be stratified by prescribed GC dose on...

View All Clinical Trials